BRIEF-GSK receives US approval for diabetes treatment Tanzeum

April 15 Tue Apr 15, 2014 1:06pm EDT

April 15 (Reuters) - Glaxosmithkline Plc

* Tanzeum (Albiglutide) receives FDA approval

* GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum Tm (Albiglutide)

* Following this approval by FDA, GSK anticipates US launch of Tanzeum in Q3 of 2014 Source text for Eikon: Further company coverage:

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.